Dendreon Shares Catch Fire

Updated from 9:39 a.m.

Dendreon (DNDN Quote) soared 43% after the biotech said regulators spelled out what they'll need to see to approve its Provenge vaccine for prostate cancer.

The Seattle-based company said Thursday morning that it got Food and Drug Administration confirmation that the agency "will accept either a positive interim or final analysis of survival from its ongoing Impact study to amend the Biologics License Application for Provenge."

Dendreon shares plunged earlier this month after the FDA asked for additional clinical data on Provenge before approving it. In March, shares had rallied after an FDA advisory panel backed approval. ...